SELLAS Life Sciences Group, Inc. - 8-K Filing

SELLAS Life Sciences reports Q3 2026 net loss of $10.1 million and announces expected topline Phase 3 REGAL trial results this month (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

4 articles from 2 sources · updated November 12, 2026, 21:15 UTC

Coverage

• SELLAS Life Sciences GAAP EPS of -$0.05 in-line Seeking Alpha · November 12, 2026, 21:11 UTC
• Erasca, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:08 UTC
• NeuroPace Inc - 8-K Filing SEC EDGAR · November 12, 2026, 21:07 UTC
• SELLAS Life Sciences Group, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:07 UTC